Mitsubishi Chemical Group. Science. Value. Life.
Explore Our Treatments

News

Important news about our latest developments in science & medicine.

Press Releases

August 29, 2023
Mitsubishi Tanabe Pharma America Presents Positive Results from Pivotal Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson’s Disease Experiencing Motor Fluctuations Read More
August 28, 2023
Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson’s Disease at 2023 International Congress of Parkinson’s Disease and Movement Disorders Society (MDS) Read More
August 17, 2023
Mitsubishi Tanabe Pharma America Announces Post-Hoc Analysis Examining Effect of Early Intervention with RADICAVA® (edaravone) on Survival and Disease Progression Milestones in People with ALS Read More
July 31, 2023
Mitsubishi Tanabe Pharma America Announces Update on Global, Phase 3b MT-1186-A02 Postmarketing Study of Oral Edaravone in ALS Read More
July 11, 2023
Mitsubishi Tanabe Pharma America to Share Details from Phase 3b RADICAVA ORS® (edaravone) Study at European Network to Cure ALS (ENCALS) Meeting 2023 Read More
July 5, 2023
Mitsubishi Tanabe Pharma America Highlights Latest Research in Parkinson’s Disease at EAN and WPC 2023 Congresses Read More
June 15, 2023
Mitsubishi Tanabe Pharma America Celebrates One-Year Anniversary of RADICAVA ORS® (edaravone) Launch in the U.S. Read More
June 6, 2023
Mitsubishi Tanabe Pharma America to Partner with ALS/MND Natural History Study Consortium to Collect Real-World Data in ALS with the Goal of Improving Patient Care Read More
May 12, 2023
Mitsubishi Tanabe Pharma America Announces Presentations at XXVIII World Congress on Parkinson’s Disease and Related Disorders Read More
April 20, 2023
Mitsubishi Tanabe Pharma America to Present Latest Findings Across ALS and Parkinson’s Disease at 2023 American Academy of Neurology Annual Meeting Read More
April 3, 2023
Mitsubishi Tanabe Pharma America, Inc. Announces Reorganization and Appoints New Leadership Read More
March 23, 2023
Mitsubishi Tanabe Pharma America Announces Enrollment Completion for Global, Phase 3b Study of RADICAVA ORS® (edaravone) in ALS Read More
March 20, 2023
Mitsubishi Tanabe Pharma America to Share ALS Research at AMCP Annual Meeting 2023 Read More
March 17, 2023
Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 2023 MDA Clinical & Scientific Conference Read More
March 16, 2023
Mitsubishi Tanabe Pharma America Announces More Than 10,000 People with ALS Treated with RADICAVA ORS® (edaravone) and/or RADICAVA® (edaravone) Read More
March 10, 2023
RADICAVA ORS® (edaravone) Added to U.S. Department of Veterans Affairs National Formulary Read More
February 27, 2023
Mitsubishi Tanabe Pharma America Announces 48-Week Results from Global, Open-Label, Phase 3 Trial of RADICAVA ORS® (edaravone) in ALS Read More
January 26, 2023
Mitsubishi Tanabe Pharma America Announces Nearly 4,000 ALS Patients in the U.S. Have Been Treated with RADICAVA ORS® (edaravone) Read More
December 6, 2022
Mitsubishi Tanabe Pharma America Announces Presentations at Virtual 33rd International Symposium on ALS/MND Read More
November 2, 2022
Mitsubishi Tanabe Pharma America Presents Interim Data from REFINE-ALS Biomarker Study at 21st Annual NEALS Meeting Read More
November 1, 2022
Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Data at 21st Annual NEALS Meeting Read More
September 28, 2022
Mitsubishi Tanabe Pharma America Celebrates Nearly 2,000 ALS Patients treated with RADICAVA ORS® (edaravone) Read More
September 21, 2022
Mitsubishi Tanabe Pharma America Presents Data on RADICAVA ORS® (edaravone) at 2022 AANEM Annual Meeting Read More
August 15, 2022
Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Survival with RADICAVA® (edaravone) Read More
June 29, 2022
Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (edaravone) Read More
June 15, 2022
RADICAVA ORS® (edaravone) Now Available in the U.S. for the Treatment of ALS Read More
June 1, 2022
Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of RADICAVA ORS® (edaravone), an Oral Treatment for ALS Read More
May 12, 2022
Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (edaravone) for the Treatment of ALS Read More
April 28, 2022
Target ALS and Mitsubishi Tanabe Pharma America Announce Winner of the First Annual Rebecca Luker Courage Award Read More
April 4, 2022
Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA® (edaravone) at 2022 American Academy of Neurology Annual Meeting Read More
April 1, 2022
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2022 American Academy of Neurology Annual Meeting Read More
March 11, 2022
Mitsubishi Tanabe Pharma America Highlights ALS Research at 2022 MDA Clinical & Scientific Conference Read More
January 12, 2022
Mitsubishi Tanabe Pharma America Announces FDA Acceptance of New Drug Application (NDA) for Oral Edaravone Formulation for the Treatment of ALS Read More
December 10, 2021
Mitsubishi Tanabe Pharma America Presents REFINE-ALS Biomarker Study Details at Virtual 32nd International Symposium on ALS/MND Read More
December 9, 2021
Mitsubishi Tanabe Pharma America Announces Results from the Global Phase 3 Safety Study of Investigational Oral Edaravone in the Treatment of ALS Read More
December 1, 2021
Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND Read More
October 15, 2021
Mitsubishi Tanabe Pharma America Announces Presentations at 146th Annual Meeting of the American Neurological Association Read More
October 6, 2021
Mitsubishi Tanabe Pharma America Highlights ALS Research at Northeast Amyotrophic Lateral Sclerosis 20th Annual Meeting Read More
August 9, 2021
Mitsubishi Tanabe Pharma America Celebrates Fourth Anniversary of U.S. Availability of RADICAVA® (edaravone) for Treatment of ALS Read More
July 27, 2021
Mitsubishi Tanabe Pharma America and Target ALS Announce Call for Nominations for First Annual Rebecca Luker Courage Award Read More
June 30, 2021
Mitsubishi Tanabe Pharma America Announces EXSERVAN™
(riluzole) is Now Available in the U.S. for the Treatment of ALS Read More
June 25, 2021
MTPA Announces PANTHERx® Selected as Exclusive Provider of U.S. Specialty Pharmacy Services for EXSERVAN™ (riluzole) Oral Film Read More
May 12, 2021
Mitsubishi Tanabe Pharma America to Present Analysis of Real-World Claims Data for Patients Treated with Edaravone During 2021 European Network to Cure ALS (ENCALS) Virtual Meeting Read More
April 20, 2021
Mitsubishi Tanabe Pharma America Presents Analysis Examining Real-World Data on ALS Patient Disease Progression Milestones Read More
March 18, 2021
Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravone on Survival and Disease Progression Milestone Events in ALS Patients Read More
March 17, 2021
Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients’ Ability to Independently Conduct Daily Activities Read More
March 3, 2021
Mitsubishi Tanabe Pharma America Announces Establishment of NeuroDiscovery Lab Research Base in Cambridge, Mass. Read More
February 8, 2021
Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S. Read More
January 21, 2021
Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole
Oral Film for ALS Treatment Read More
January 14, 2021
Mitsubishi Tanabe Pharma America Announces Enhancements to
Out-of-Pocket Assistance Program for Eligible ALS Patients
Treated with RADICAVA® (edaravone) Read More
January 7, 2021
Mitsubishi Tanabe Pharma America Revises REFINE-ALS Biomarker
Study Process to Enable Remote Participation Read More
December 22, 2020
Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS Read More
December 14, 2020
Mitsubishi Tanabe Pharma America Announces Initiation of Postmarketing Commitment Study Assessing
Daily Dosing of Oral Edaravone in Patients with ALS Read More
December 11, 2020
Mitsubishi Tanabe Pharma America Presents Real-World
Experience Outcomes During IV Edaravone Treatment at
Virtual 31st International Symposium on ALS/MND Read More
December 3, 2020
Mitsubishi Tanabe Pharma America Announces Presentations of ALS Data at Virtual 31st International Symposium on ALS/MND Read More
November 30, 2020
Post-Hoc Analysis of ALS Treatment Study Looks at
Multiple Staging Systems Read More
November 9, 2020
Mitsubishi Tanabe Pharma America Announces the Global Phase 3 Study of Oral Edaravone for ALS has Completed Enrollment Read More
October 27, 2020
Mitsubishi Tanabe Pharma America Celebrates ALS Caregiver & Screenwriter Featured In MDA Kevin Hart Kids Telethon Read More
October 9, 2020
Mitsubishi Tanabe Pharma America Announces Poster Presentation
of ALS Data at American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2020 Meeting Read More
September 30, 2020
Mitsubishi Tanabe Pharma America Announces Presentations at Northeast Amyotrophic Lateral Sclerosis 19th Annual Meeting Read More
August 24, 2020
Mitsubishi Tanabe Pharma America Announces Enrollment Has Resumed for the Global Phase 3 Study of Oral Edaravone for ALS Read More
August 6, 2020
Mitsubishi Tanabe Pharma America Honors Third Anniversary of
RADICAVA® (Edaravone) in the U.S. & Company’s Support of ALS Community Read More
June 19, 2020
Phase-3 Clinical Trial of MT-7117 Initiated in the U.S. for Rare Diseases, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) Read More
May 20, 2020
Mitsubishi Tanabe Pharma America Announces Launch of the JourneyMate Program, Offering Live Nurse Educational Phone Support for ALS Patients and Caregivers Read More
May 5, 2020
Mitsubishi Tanabe Pharma America Marks Third Anniversary of FDA Approval and Reports More Than 5,000 Patients with ALS Treated with RADICAVA® (Edaravone) Read More
March 24, 2020
New Post-Hoc Analysis of Phase 3 Study Examines Edaravone in ALS Patients with Bulbar and Limb Onset Read More
March 17, 2020
MTPA’s Response to COVID-19 Read More
February 7, 2020
Mitsubishi Tanabe Pharma America Celebrates Fourth Year in The U.S. Serving The ALS Community Read More
December 4, 2019
Mitsubishi Tanabe Pharma America to Present Real-World Data on ALS Treatment at the 30th International Symposium on ALS/MND Read More
December 2, 2019
Mitsubishi Tanabe Pharma America to Spotlight Progress in ALS Research at 30th International Symposium on ALS/MND Read More
November 25, 2019
Mitsubishi Tanabe Pharma America Announces Initiation of Phase 3 Study Evaluating Investigational Oral Formulation of Edaravone for ALS Read More
November 15, 2019
Mitsubishi Tanabe Pharma America to Receive Essey Commitment to Cures Award from the ALS Community for Extensive Efforts and Collaboration in ALS Research, Development and Education Read More
October 24, 2019
First Patient Enrolled in MTPA REFINE-ALS Biomarker Study Read More
September 26, 2019
Mitsubishi Tanabe Pharma America Announces Appointment of Gustavo A. Suarez Zambrano, M.D., as Vice President, Medical Affairs Read More
September 23, 2019
Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient- Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson’s Disease and Movement Disorders Read More
September 20, 2019
Mitsubishi Tanabe Pharma America to Present on ALS Clinical Programs at 2019 Muscle Study Group Annual Scientific Meeting Read More
August 28, 2019
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated in the United States for Parkinson’s Disease Read More
August 8, 2019
More Than 4,000 U.S. Patients with ALS Treated with RADICAVA® (edaravone) in Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports Read More
July 23, 2019
Mitsubishi Tanabe Pharma America Presents at 2019 National ALS Registry Annual Meeting in Atlanta Read More
May 6, 2019
MTPA Announces Nationwide Database of ALS Infusion Services to Help Patients and Caregivers Identify Local Providers Read More
May 3, 2019
Oxford Biodynamics Joins ALS Biomarker Study Sponsored by Mitsubishi Tanabe Pharma America Read More
May 2, 2019
Post-Hoc Analyses of ALS Treatment Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency Read More
April 11, 2019
Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference Read More
April 4, 2019
Mitsubishi Tanabe Pharma America Announces Names of Teens And Young Adults Chosen for Inclusion In ALSO US™ Initiative Read More
March 28, 2019
Mitsubishi Tanabe Pharma America Announces Collaboration with Massachusetts General Hospital on ALS Biomarker Study Read More
March 1, 2019
Mitsubishi Tanabe Pharma America Appoints Sam Shum as Vice President of Operations and Strategy Read More
February 21, 2019
Mitsubishi Tanabe Pharma America Accepting Independent Research Program Submissions for RADICAVA® (edaravone) Through March 8 Read More
February 6, 2019
Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients in the U.S. Have Been Treated With RADICAVA® (edaravone) Read More
January 31, 2019
MTPA Launches National Online Directory of ALS Specialists and Neurologists at Multidisciplinary Centers Read More
December 6, 2018
Mitsubishi Tanabe Pharma America Announces Collaborative Study to Identify and Measure Biomarkers in People With ALS Read More
November 28, 2018
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 29th International Symposium on ALS/MND in Glasgow Read More
November 15, 2018
Mitsubishi Tanabe Pharma Group Companies to Present New Data on Investigational Oral Formulation at MNDA Read More
November 5, 2018
Mitsubishi Tanabe Pharma America’s ALSO US™ Initiative Begins Accepting Artistic Submissions from Teens Impacted by ALS Read More
October 4, 2018
Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ALS Treatment Read More
September 24, 2018
Mitsubishi Tanabe Pharma America Appoints Joseph Scalia As Vice President of Sales and Marketing Read More
August 8, 2018
Mitsubishi Tanabe Pharma America Announces over 3,000 Patients in the U.S. With ALS Have Been Treated With RADICAVA® (Edaravone) in the Last Year Read More
June 21, 2018
Mitsubishi Tanabe Pharma America to Present Data on Radicava® (Edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting Read More
May 7, 2018
Mitsubishi Tanabe Pharma America Marks One-year Anniversary of Only FDA-approved ALS Treatment Option in the Last 20 Years Read More
April 18, 2018
Mitsubishi Tanabe Pharma America and Neuroderm Announce Parkinson’s Disease Presentations at American Academy of Neurology Annual Meeting Read More
April 18, 2018
Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting Read More
April 9, 2018
Health Canada Accepts Mitsubishi Tanabe Pharma Corporation’s NDS Filing for Edaravone to Treat ALS, Grants Priority Review Read More
December 20, 2017
Mitsubishi Tanabe Pharma America Initiates Independent Research Program for RADICAVA® (edaravone) Read More
December 5, 2017
Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston Read More
November 30, 2017
Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary Read More
November 21, 2017
Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access Read More
November 16, 2017
Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available Read More
September 7, 2017
Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal Read More
September 6, 2017
Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services Read More
August 9, 2017
MTPA Perspective Regarding Medicare Coverage Read More
August 8, 2017
First FDA-approved Treatment for ALS in 22 Years Now Available in U.S. Read More
August 1, 2017
MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America Read More
July 25, 2017
MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVA™ (Edaravone) Read More
June 30, 2017
Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients Read More
May 18, 2017
Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVA™ (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting Read More
May 5, 2017
RADICAVA™ (edaravone) Prescribing Information Read More
May 5, 2017
MT Pharma America Announces FDA Approval of RADICAVA™ (Edaravone), the First New Treatment Option for ALS in More Than 20 Years Read More
April 20, 2017
MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting Read More
December 9, 2016
12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND Read More
September 20, 2016
The ALS Association Welcomes MT Pharma America as National Corporate Sponsor Read More
August 30, 2016
FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS Read More
June 20, 2016
Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States Read More
April 20, 2016
Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting Read More
Load More

Looking for more information?

Media Assets
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America, Inc.
This link will take you to a website to which our Privacy Policy and Terms of Use does not apply. Mitsubishi Tanabe Pharma America, Inc. does not control the content of this third-party site.
Continue
Cancel